What is cTIF?
cTIF (concomitant Transoral Incisionless Fundoplication) is a TIF 2.0 procedure preceded by a hiatal hernia repair for patients with a hernia greater than 2 cm.
What is GERD?
Gastroesophageal reflux disease (GERD) is caused by a gradual deterioration of the antireflux barrier. The antireflux barrier (ARB) consists of the crural diaphragm, the LES and its sling fibers, and the gastroesophageal flap valve.29 These three factors contribute to the mechanical and physiologic barriers to reflux. cTIF resolves the root cause of reflux by addressing all three components of the ARB.
What does cTIF Accomplish?
- Creates an omega shaped valve, helping to restore native anatomy
- Recreates the Angle of HIS with 270° anterior and posterior wrap
- Elongates the distal esophagus and restores the distal high-pressure zone
- Avoids disruption of the lesser curvature of the stomach
- Potentially less dissection of short gastric vessels and preserving blood supply
- Spares the fundus preserving the accommodation function
- No twisting or torquing of gastric folds
How effective is cTIF?
- Significant Reduction in Subject Reported Symptoms of GERD15
- Lower Rate of Early and Serious Adverse Events When Compared to Laparoscopic NISSEN Fundoplication (LNF)30
- Higher Rate of Decreased or Discontinued PPI Use At Six And Twelve Months when Compared to LNF30
- Fewer reports of Dysphagia and Gas Bloat Associated with Traditional AntiReflux Procedures15
What is the Data on cTIF?
- 32,000 Procedures worldwide since original EsophyX® device clearance in 200
- 1,500 Unique patients studied in over
- 75 centers with consistent outcomes
- 140 Peer-reviewed clinical papers in respected gastroenterology and surgical journals
- 4 Published randomized control trials; two with sham controlled arms
What are the Outcomes of cTIF?
- 73% Decrease in GERD
- 83% Decrease in regurgitation
- 89% Reduction in PPI use
- 94% Improvement in DeMeester score
